<DOC>
	<DOC>NCT02001584</DOC>
	<brief_summary>The purpose of this study is to investigate the safety, tolerability and pharmacokinetics of a predefined dose range of co-administered Baclofen and Memantine in non-obese (Part A) and obese (Part B), otherwise healthy subjects.</brief_summary>
	<brief_title>A Study to Examine the, Safety, Tolerability and Pharmacokinetics Co-Administered Baclofen and Memantine in Obese and Lean, Otherwise Healthy Adults</brief_title>
	<detailed_description />
	<mesh_term>Memantine</mesh_term>
	<criteria>1. Adult males or females aged 18 to 45 years inclusive; 2. Subjects with body mass index: For Part A: ≥18 kg/m² and ≤25 kg/m²; For Part B: ≥33 kg/m² and ≤40 kg/m². 3. Subjects with a total body weight of ≥50 kg (Part A and Part B); 4. Subjects who are healthy as determined by the Investigator based on pre study medical history, physical examination, vital signs (blood pressure, pulse rate, respiratory rate and body temperature) and 12lead ECG at screening and each admission; 5. Subjects whose clinical laboratory test results are not clinically relevant and are acceptable to the Investigator at screening and each admission; 6. Aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase and bilirubin ≤1.5 x upper limit of normal (ULN); 7. Subjects who are negative for hepatitis B surface antigen (HBsAg), hepatitis C antibody and human immunodeficiency virus (HIV) I and II tests at screening; 8. Subjects who are negative for drugs of abuse and alcohol tests at screening and each admission; 9. Subjects who are nonsmokers or who have not smoked or used nicotinecontaining products for at least 3 months prior to screening; 10. Subjects with an estimated creatinine clearance ≥100 mL/minute for male subjects or ≥90 mL/minute for female subjects (CockcroftGault method) at screening; 11. Subjects who are able and willing to give written informed consent.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>